CSI was contacted by a client that urgently required medical devices to be delivered to Russia, Ukraine, Belarus, and Georgia for a large oncology trial.
These devices/markers were required during the patient screening visit. These devices are only applied to a very limited number of patients under a standard of care; however, due to the increased level of follow up required in the environment of the clinical trial, the devices were being applied to all patients. The client thought initially that the sites would be able to source themselves, but the quantities required were higher than the UK and Germany joint monthly number of units, and deliveries had to be arranged on demand to 100 sites.
The quantities were so large compared to normal demand that they placed strain on the manufacturer’s own production and supply chain capability.
CSI worked closely with the client’s medical team to identify options for products with the same characteristics as alternative/option B solutions.
From a combination of the main and secondary source, CSI adequately supplied the study and avoided delays to patient recruitment.
We ensured that all required documentation was in place for smooth import and distribution, forecasted demand, and developed a safety net stock level to respond to variable patient recruitment levels.